Baxter International Inc. (NYSE:BAX) Receives $41.20 Average Price Target from Analysts

Baxter International Inc. (NYSE:BAX - Get Free Report) has earned an average recommendation of "Hold" from the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $41.20.

Several brokerages have commented on BAX. Evercore ISI dropped their target price on shares of Baxter International from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Tuesday, July 2nd. Morgan Stanley lowered Baxter International from an "equal weight" rating to an "underweight" rating and decreased their target price for the stock from $39.00 to $30.00 in a report on Monday, July 15th. Wells Fargo & Company reduced their price objective on shares of Baxter International from $44.00 to $40.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price objective on shares of Baxter International from $44.00 to $42.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 7th. Finally, StockNews.com raised shares of Baxter International from a "hold" rating to a "buy" rating in a report on Tuesday, October 22nd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LSV Asset Management bought a new stake in shares of Baxter International during the 2nd quarter worth $140,296,000. Bank of New York Mellon Corp lifted its stake in Baxter International by 73.2% in the second quarter. Bank of New York Mellon Corp now owns 6,772,533 shares of the medical instruments supplier's stock valued at $226,541,000 after purchasing an additional 2,862,626 shares during the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in shares of Baxter International in the second quarter valued at $67,263,000. Coho Partners Ltd. bought a new position in shares of Baxter International during the 3rd quarter worth $57,229,000. Finally, Shapiro Capital Management LLC boosted its position in Baxter International by 19.7% during the second quarter. Shapiro Capital Management LLC now owns 3,285,048 shares of the medical instruments supplier's stock worth $109,885,000 after purchasing an additional 541,575 shares during the period. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Trading Down 0.1 %

Shares of Baxter International stock traded down $0.02 during trading on Wednesday, reaching $35.97. 1,295,535 shares of the company were exchanged, compared to its average volume of 4,047,256. The business has a 50-day moving average price of $37.66 and a 200-day moving average price of $36.30. The firm has a market capitalization of $18.33 billion, a price-to-earnings ratio of 6.90, a P/E/G ratio of 1.28 and a beta of 0.59. The company has a quick ratio of 0.91, a current ratio of 1.40 and a debt-to-equity ratio of 1.35. Baxter International has a twelve month low of $32.06 and a twelve month high of $44.01.

Baxter International (NYSE:BAX - Get Free Report) last posted its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. Baxter International had a net margin of 16.51% and a return on equity of 18.06%. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.75 billion. During the same period last year, the business posted $0.55 earnings per share. The business's revenue for the quarter was up 2.8% compared to the same quarter last year. Sell-side analysts anticipate that Baxter International will post 2.96 EPS for the current fiscal year.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.